01 Feb A SIGNAL OF MYOCARDITIS / PERICARDITIS ASSOCIATED WITH PFIZER-BIONTECH’S COVID-19 VACCINE, COMIRNATY (BNT162B2)
Posted at 09:27h
in
The South African Health Products Regulatory Authority (SAHPRA) would like to inform you of a signal of myocarditis / pericarditis associated with Pfizer-BioNTech’s Covid-19 vaccine, Comirnaty® (BNT162b2). The Pfizer/BioNTech Comirnaty® Vaccine was approved by SAHPRA in March 2021. The authorisation was done in terms of Section 21 of the Medicines and Related Substance Act, (Act 101 of 1965) as amended, a mechanism in the Medicines Act that enables emergency use access subject to certain conditions
2021 Aug
Download latest version
Version:
1
Date Updated:
19/08/2021
File Type:
pdf
Category:
Safety Alerts